[1] Hadker N, Egan J, Sanders J, et al. Understanding the burden of illness associated with hypoparathyroidism reported among patients in the paradox study[J].Endocr Pract,2014, 20(7): 671-679.
[2] 全婷婷,李悦芃,王 鸥,等.成年起病的原发性甲状旁腺功能减退症200例临床分析[J].中华内科杂志, 2017, 56(1): 19-23.
[3] Bollerslev J, Rejnmark L, Marcocci C, et al. European Society of Endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults [J].Eur J Endocrinol,2015,173(2):G1-20.
[4] Brandi M L, Bilezikian J P, Shoback D, et al.Management of hypoparathyroidism: summary statement and guidelines[J]. Clin Endocrinol Metab,2016, 101(6): 2273-2283.
[5] Eremkina A K, Mokrysheva N G, Kovaleva E V, et al. Recombinant human parat-hyroid hormone in the therapy of hypoparathyroidism[J]. Ter Arkh,2017, 89(10): 80-86.
[6] Moushumi L, Rajarshi M. Primary hypoparathyroidism misdiagnosed as epilepsy-a case report[J]. EJIFCC,2014, 25(2): 195-198.
[7] 原玉琴. 甲状旁腺功能减退症误诊6例分析[J].中国误诊学杂志,2009,9(34): 8441-8442.